The advent of BTK inhibitors has revolutionized the treatments of B cell malignancies, especially chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL). The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.